Brexanolone: First Global Approval

Abstract

Brexanolone (ZULRESSO™) is an intravenously administered, small molecule, neuroactive steroid GABAA receptor positive allosteric modulator that was developed by Sage Therapeutics under license to the University of California for the treatment of postpartum depression (PPD). The formulation is a mixture of allopregnanolone, an endogenous inhibitory pregnane neurosteroid, and sulfobutylether-beta-cyclodextrin (a solubilizing agent). In mid-March 2019 brexanolone received its first global approval in the USA for the treatment of PPD in adult women. This article summarizes the milestones in the development of brexanolone leading to its first approval for the treatment of adult women with PPD.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Frieder A, Fersh M, Hainline R, et al. Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs. 2019;33(3):265–82.

    CAS  PubMed  Google Scholar 

  2. 2.

    Kose S, Cetin M. Brexanolone: an allosteric modulator of GABA-A receptors in the rapid treatment of postpartum depression. Psychiatry Clin Psychopharmacol. 2017;27(4):326–8.

    Article  CAS  Google Scholar 

  3. 3.

    Muzik M, Marcus SM, Heringhausen JE, et al. When depression complicates childbearing: guidelines for screening and treatment during antenatal and postpartum obstetric care. Obstet Gynecol Clin N Am. 2009;36(4):771–88.

    Article  Google Scholar 

  4. 4.

    Schiller CE, Schmidt PJ, Rubinow DR. Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology. 2014;231:3557–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Schiller CE, Meltzer-Brody S, Rubinow D. The role of reproductive hormones in postpartum depression. CNS Spectr. 2015;20(1):48–59.

    Article  PubMed  Google Scholar 

  6. 6.

    US FDA. FDA approves first treatment for post-partum depression. 2019. http://www.fda.gov/. Accessed 22 Mar 2019.

  7. 7.

    Sage Therapeutics Inc. ZULRESSO (Brexanolone): US prescribing information. 2019. http://www.fda.gov/. Accessed 22 Mar 2019.

  8. 8.

    Zorumski CF, Paul SM, Izumi Y, et al. Neurosteroids, stress and depression: potential therapeutic targets. Neurosci Biobehav Rev. 2013;37(1):109–22.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Hoffmann E, Wald J, Colquhoun H. Evaluation of breast milk concentrations following brexanolone iv administration to healthy lactating women [abstract no. 850]. Am J Obstet Gynecol. 2019;220(1 Suppl):S554.

    Article  Google Scholar 

  10. 10.

    Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017;390(10093):480–9.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392(10152):1058–70.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Kanes SJ, Colquhoun H, Doherty J, et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol. 2017;32(2):e2576.

    Article  CAS  PubMed Central  Google Scholar 

  13. 13.

    Clemson C, Meltzer-Brody S, Colquhoun H, et al. Brexanolone iv efficacy in postpartum depression in three pivotal trials: montgomery-asberg depression rating scale assessment [abstract no. 86]. Am J Obstet Gynecol. 2019;220(1 Suppl):S69–70.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lesley J. Scott.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Brexanolone: First Global Approval. Drugs 79, 779–783 (2019). https://doi.org/10.1007/s40265-019-01121-0

Download citation